Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled multiple-dose study of EDP1815 formulations in healthy adults
NL-OMON49769Phase 1Active, not recruiting
- Sponsor
- Evelo Biosciences
- Start
- Dec 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease comparing EDP1815 with Placebo (2 arms). Primary endpoints: Delayed-type hypersensitivity after KLH rechallenge, Anti-KLH serology and 6 more. Started Dec 2019; status: active, not recruiting.
02
Drugs
EDP1815
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON49769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49769.